AtaiBeckley stock has delivered a very large 3 year gain, and the broader valuation checks currently lean expensive, with the market multiple suggesting investors are paying up for the story after the Eli Lilly buyout announcement and recent regulatory tailwinds.

• AtaiBeckley has returned about 248.5% over the past 3 years, which puts a lot of recent optimism into the current share price.
• The agreed Eli Lilly acquisition and supportive FDA guidance on psychedelic therapies can underpin confidence in AtaiBeckley’s pipeline, but the deal still depends on shareholder and regulatory approvals, so execution and timing remain important risks for valuation.
• AtaiBeckley scores 1 out of 6 on the broader valuation checks, which points to a stock that currently looks more like a rich pricing than a clear bargain.

The issue now is whether the agreed takeover terms and recent rally leave enough upside in AtaiBeckley’s valuation for investors who are considering the stock today.

Is AtaiBeckley Getting Expensive on Book Value?

P/B is often used for drug developers like AtaiBeckley because much of the value investors focus on sits in the balance sheet and R&D assets rather than current earnings. AtaiBeckley currently trades on a P/B of about 13.4x, compared with a Pharmaceuticals industry average of around 2.5x. That is a very wide gap, suggesting investors are willing to pay a high price for each dollar of the company’s net assets.

Even against a peer average P/B of roughly 22.6x, AtaiBeckley sits at the higher end of what many investors might consider a rich range for a stock that is still dependent on clinical progress and future approvals. The agreed Eli Lilly deal and FDA guidance on psychedelic therapies help explain why sentiment is strong, but they also appear to be well reflected in the current multiple.

On the P/B yardstick, AtaiBeckley appears overvalued relative to both its industry and specialist peers.

The AtaiBeckley Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for AtaiBeckley pick up where this valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, based on a series of grounded scenarios that live on the Community page. Each Narrative ties a fair value estimate to a particular set of potential catalysts and risks for AtaiBeckley, so you can track over time which story the company appears to be following.

Share your own narrative on AtaiBeckley stock to be one of the first voices in the Simply Wall St community, laying out a number-driven view on whether Eli Lilly's up to US$3.8b acquisition and the progress of BPL-003 ultimately deliver on today's pricing.

Do you think there's more to the story for AtaiBeckley? Head over to our Community to see what others are saying!

The Bottom Line

AtaiBeckley currently screens as overvalued on the market multiples, with the extreme gap to industry P/B levels pointing to expectations that are already ambitious. With the broader valuation checks scoring poorly, the bar for future execution around the Eli Lilly acquisition terms and the clinical path for BPL-003 looks high. The real divide between bulls and bears now is whether AtaiBeckley can deliver enough tangible regulatory and development progress to keep justifying such a premium multiple, or whether sentiment eventually cools and the valuation settles closer to sector norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.